Abhinav Nath

Associate Professor, Medicinal Chemistry

Department of Medicinal Chemistry, Medicinal Chemistry Faculty, Nath Lab, Plein Center in Geriatrics Faculty, School Faculty

Telephone: (206) 616-4586

Email: anath@uw.edu

Website: Nath Lab

Expertise:
Central Nervous System, Computational Modeling, Drug Discovery, Molecular Biophysics, Protein Dynamics

Education

  • B.A. (Chemistry and Biology), University of Virginia
  • Ph.D. (Medicinal Chemistry/Biomolecular Structure & Design), University of Washington
  • Postdoc (Molecular Biophysics & Biochemistry), Yale University

Research Interests

  • Protein aggregation in Alzheimer’s disease and related dementias
  • Protein self-assembly
  • Biologics and protein-based therapeutics

Taking Students: Yes

Biography

Abhinav “Abhi” Nath earned his BA (in Biology and Chemistry) from the University of Virginia in 2003, and his PhD (in Medicinal Chemistry and Biomolecular Structure & Design) from the University of Washington in 2008, where he worked with Bill Atkins on understanding the mechanisms of substrate binding by cytochrome P450s and other drug-metabolizing enzymes. He then moved to Yale University for postdoctoral training with professors Liz Rhoades and Andrew Miranker, where he was an American Heart Association Postdoctoral Fellow and studied intrinsically disordered and amyloid-forming proteins using single-molecule fluorescence and computational methods.

The Nath lab is interested in understanding the roles of protein dynamics in human health and disease. Proteins display a fascinating spectrum of dynamic behavior, ranging from some that are almost static to others that rapidly interconvert between a diverse ensemble of structures. The nature, amplitude and timescales of protein conformational fluctuations can be crucial to biological functions such as enzyme catalysis and intracellular signaling. Mutations, post-translational modifications and environmental factors can perturb protein dynamics – and hence normal function – in ways that are difficult to predict.

Abhi and his group are developing new and powerful methods to characterize and control protein dynamics, building on recent advances in biophysics, biochemistry and pharmacology from groups around the world. They focus on proteins involved in degenerative disorders (such as Alzheimer’s disease), the oxidative stress response, and drug metabolism.

Recent Publications

Investigating the association between CYP2J2 inhibitors and QT prolongation: a literature review. Wiley AM, Yang J, Madhani R, Nath A, Totah RA. Drug Metab Rev. 2024 Mar 20:1-19. doi: 10.1080/03602532.2024.2329928. Online ahead of print. PMID: 38478383 Review.

The origins of nonideality exhibited by monoclonal antibodies and Fab fragments in human serum. Larsen HA, Atkins WM, Nath A. Protein Sci. 2023 Dec;32(12):e4812. doi: 10.1002/pro.4812. PMID: 37861473

The Utility of Mixed Effects Models in the Evaluation of Complex Genomic Traits In Vitro. Alade N, Nath A, Isoherranen N, Thummel KE. Drug Metab Dispos. 2023 Nov;51(11):1455-1462. doi: 10.1124/dmd.123.001260. Epub 2023 Aug 10. PMID: 37562955

Low molecular weight ligands bind to CYP3A4 via a branched induced fit mechanism: Implications for O2 binding. Redhair M, Nath A, Hackett JC, Atkins WM. Arch Biochem Biophys. 2023 May 1;739:109582. doi: 10.1016/j.abb.2023.109582. Epub 2023 Mar 21.

MitoNEET’s Reactivity of Lys55 toward Pyridoxal Phosphate Demonstrates its Activity as a Transaminase Enzyme. Kunk C, Kruger J, Mendoza G, Markitan J, Bias T, Mann A, Nath A, Geldenhuys WJ, Menze MA, Konkle ME. ACS Chem Biol. 2022 Oct 21;17(10):2716-2722. doi: 10.1021/acschembio.2c00572. Epub 2022 Oct 4.

Structure-Activity Relationships of Novel Tau Ligands: Passive Fibril Binders and Active Aggregation Inhibitors. Baggett DW, Nath A. ACS Chem Biol. 2022 Mar 18;17(3):701-708. doi: 10.1021/acschembio.2c00012. Epub 2022 Feb 11.

Probing interactions of therapeutic antibodies with serum via second virial coefficient measurements. Larsen HA, Atkins WM, Nath A. Biophys J. 2021 Sep 21;120(18):4067-4078. doi: 10.1016/j.bpj.2021.08.007. Epub 2021 Aug 10.

 

Corrigendum to “In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation” [Biochem. Pharmacol. 123(2017)85-96]. Sager JE, Tripathy S, Price LSL, Nath A, Chang J, Stephenson-Famy A, Isoherranen N. Biochem Pharmacol. 2021 Jan;183:114306. doi: 10.1016/j.bcp.2020.114306. Epub 2020 Nov 5.

Identification of a novel tedizolid resistance mutation in rpoB of MRSA after in vitro serial passage. Shen T, Penewit K, Waalkes A, Xu L, Salipante SJ, Nath A, Werth BJ. J Antimicrob Chemother. 2021 Jan 19;76(2):292-296. doi: 10.1093/jac/dkaa422.